No Cover Image

Journal article 748 views 118 downloads

The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats

Thomas S. Webberley, Giulia Masetti, Laura Baker, Jordanna Dally, Timothy R. Hughes, Julian R. Marchesi, Alison A. Jack, Sue F. Plummer, Guru Ramanathan, Paul Facey Orcid Logo, Daryn R. Michael

Frontiers in Nutrition, Volume: 8

Swansea University Authors: Laura Baker, Paul Facey Orcid Logo

  • 59001.pdf

    PDF | Version of Record

    © 2021 Webberley, Masetti, Baker, Dally, Hughes, Marchesi, Jack, Plummer, Ramanathan, Facey and Michael. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY)

    Download (707.39KB)

Check full text

DOI (Published version): 10.3389/fnut.2021.778289

Abstract

The anti-inflammatory and cholesterol lowering capabilities of probiotic bacteria highlight them as potential prophylactics against chronic inflammatory diseases, particularly cardiovascular disease. Previous studies in silico, in vitro, and in vivo suggest that the Lab4 probiotic consortium may har...

Full description

Published in: Frontiers in Nutrition
ISSN: 2296-861X
Published: Frontiers Media SA 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa59001
first_indexed 2021-12-31T16:28:37Z
last_indexed 2022-01-01T04:25:28Z
id cronfa59001
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2021-12-31T16:31:49.2363252</datestamp><bib-version>v2</bib-version><id>59001</id><entry>2021-12-13</entry><title>The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats</title><swanseaauthors><author><sid>e30f64446a8c5cf9a49d8ee54d316c78</sid><firstname>Laura</firstname><surname>Baker</surname><name>Laura Baker</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>dc25910b8004b2694df68ed7426e1286</sid><ORCID>0000-0002-3229-0255</ORCID><firstname>Paul</firstname><surname>Facey</surname><name>Paul Facey</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-12-13</date><deptcode>MEDS</deptcode><abstract>The anti-inflammatory and cholesterol lowering capabilities of probiotic bacteria highlight them as potential prophylactics against chronic inflammatory diseases, particularly cardiovascular disease. Previous studies in silico, in vitro, and in vivo suggest that the Lab4 probiotic consortium may harbour such capabilities and in the current study, we assessed plasma levels of cytokines/chemokines, short chain fatty acids and lipids and faecal levels of bile acids in a subpopulation of healthy Wistar rats included in 90-day repeat dose oral toxicity study. In the rats receiving Lab4, circulating levels of pro-inflammatory interleukin-6, tumour necrosis factor-&#x3B1; and keratinocyte chemoattractant/growth regulated oncogene were significantly lower compared to the control group demonstrating a systemic anti-inflammatory effect. These changes occurred alongside significant reductions in plasma low density lipoprotein cholesterol and increases in faecal bile acid excretion implying the ability to lower circulating cholesterol via the deconjugation of intestinal bile acids. Correlative analysis identified significant associations between plasma tumour necrosis factor-&#x3B1; and the plasma total cholesterol:high density lipoprotein cholesterol ratio and faecal levels of bifidobacteria in the Lab4 rats. Together, these data highlight Lab4 supplementation as a holistic approach to CVD prevention and encourages further studies in humans.</abstract><type>Journal Article</type><journal>Frontiers in Nutrition</journal><volume>8</volume><journalNumber/><paginationStart/><paginationEnd/><publisher>Frontiers Media SA</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2296-861X</issnElectronic><keywords>probiotic, inflammation, SCFA, cholesterol, bile, cardiovascular</keywords><publishedDay>25</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-11-25</publishedDate><doi>10.3389/fnut.2021.778289</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>National Institute of Health Research (NIHR), the Biomedical Research Centre (BRC) based at Imperial College London, and Imperial College Healthcare NHS Trust.</funders><lastEdited>2021-12-31T16:31:49.2363252</lastEdited><Created>2021-12-13T16:10:18.2224831</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Thomas S.</firstname><surname>Webberley</surname><order>1</order></author><author><firstname>Giulia</firstname><surname>Masetti</surname><order>2</order></author><author><firstname>Laura</firstname><surname>Baker</surname><order>3</order></author><author><firstname>Jordanna</firstname><surname>Dally</surname><order>4</order></author><author><firstname>Timothy R.</firstname><surname>Hughes</surname><order>5</order></author><author><firstname>Julian R.</firstname><surname>Marchesi</surname><order>6</order></author><author><firstname>Alison A.</firstname><surname>Jack</surname><order>7</order></author><author><firstname>Sue F.</firstname><surname>Plummer</surname><order>8</order></author><author><firstname>Guru</firstname><surname>Ramanathan</surname><order>9</order></author><author><firstname>Paul</firstname><surname>Facey</surname><orcid>0000-0002-3229-0255</orcid><order>10</order></author><author><firstname>Daryn R.</firstname><surname>Michael</surname><order>11</order></author></authors><documents><document><filename>59001__21980__54395374709c464d84b369b0b9a9691a.pdf</filename><originalFilename>59001.pdf</originalFilename><uploaded>2021-12-31T16:30:14.4684079</uploaded><type>Output</type><contentLength>724367</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2021 Webberley, Masetti, Baker, Dally, Hughes, Marchesi, Jack, Plummer, Ramanathan, Facey and Michael. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY)</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2021-12-31T16:31:49.2363252 v2 59001 2021-12-13 The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats e30f64446a8c5cf9a49d8ee54d316c78 Laura Baker Laura Baker true false dc25910b8004b2694df68ed7426e1286 0000-0002-3229-0255 Paul Facey Paul Facey true false 2021-12-13 MEDS The anti-inflammatory and cholesterol lowering capabilities of probiotic bacteria highlight them as potential prophylactics against chronic inflammatory diseases, particularly cardiovascular disease. Previous studies in silico, in vitro, and in vivo suggest that the Lab4 probiotic consortium may harbour such capabilities and in the current study, we assessed plasma levels of cytokines/chemokines, short chain fatty acids and lipids and faecal levels of bile acids in a subpopulation of healthy Wistar rats included in 90-day repeat dose oral toxicity study. In the rats receiving Lab4, circulating levels of pro-inflammatory interleukin-6, tumour necrosis factor-α and keratinocyte chemoattractant/growth regulated oncogene were significantly lower compared to the control group demonstrating a systemic anti-inflammatory effect. These changes occurred alongside significant reductions in plasma low density lipoprotein cholesterol and increases in faecal bile acid excretion implying the ability to lower circulating cholesterol via the deconjugation of intestinal bile acids. Correlative analysis identified significant associations between plasma tumour necrosis factor-α and the plasma total cholesterol:high density lipoprotein cholesterol ratio and faecal levels of bifidobacteria in the Lab4 rats. Together, these data highlight Lab4 supplementation as a holistic approach to CVD prevention and encourages further studies in humans. Journal Article Frontiers in Nutrition 8 Frontiers Media SA 2296-861X probiotic, inflammation, SCFA, cholesterol, bile, cardiovascular 25 11 2021 2021-11-25 10.3389/fnut.2021.778289 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University National Institute of Health Research (NIHR), the Biomedical Research Centre (BRC) based at Imperial College London, and Imperial College Healthcare NHS Trust. 2021-12-31T16:31:49.2363252 2021-12-13T16:10:18.2224831 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Thomas S. Webberley 1 Giulia Masetti 2 Laura Baker 3 Jordanna Dally 4 Timothy R. Hughes 5 Julian R. Marchesi 6 Alison A. Jack 7 Sue F. Plummer 8 Guru Ramanathan 9 Paul Facey 0000-0002-3229-0255 10 Daryn R. Michael 11 59001__21980__54395374709c464d84b369b0b9a9691a.pdf 59001.pdf 2021-12-31T16:30:14.4684079 Output 724367 application/pdf Version of Record true © 2021 Webberley, Masetti, Baker, Dally, Hughes, Marchesi, Jack, Plummer, Ramanathan, Facey and Michael. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) true eng http://creativecommons.org/licenses/by/4.0/
title The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats
spellingShingle The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats
Laura Baker
Paul Facey
title_short The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats
title_full The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats
title_fullStr The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats
title_full_unstemmed The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats
title_sort The Impact of Lab4 Probiotic Supplementation in a 90-Day Study in Wistar Rats
author_id_str_mv e30f64446a8c5cf9a49d8ee54d316c78
dc25910b8004b2694df68ed7426e1286
author_id_fullname_str_mv e30f64446a8c5cf9a49d8ee54d316c78_***_Laura Baker
dc25910b8004b2694df68ed7426e1286_***_Paul Facey
author Laura Baker
Paul Facey
author2 Thomas S. Webberley
Giulia Masetti
Laura Baker
Jordanna Dally
Timothy R. Hughes
Julian R. Marchesi
Alison A. Jack
Sue F. Plummer
Guru Ramanathan
Paul Facey
Daryn R. Michael
format Journal article
container_title Frontiers in Nutrition
container_volume 8
publishDate 2021
institution Swansea University
issn 2296-861X
doi_str_mv 10.3389/fnut.2021.778289
publisher Frontiers Media SA
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description The anti-inflammatory and cholesterol lowering capabilities of probiotic bacteria highlight them as potential prophylactics against chronic inflammatory diseases, particularly cardiovascular disease. Previous studies in silico, in vitro, and in vivo suggest that the Lab4 probiotic consortium may harbour such capabilities and in the current study, we assessed plasma levels of cytokines/chemokines, short chain fatty acids and lipids and faecal levels of bile acids in a subpopulation of healthy Wistar rats included in 90-day repeat dose oral toxicity study. In the rats receiving Lab4, circulating levels of pro-inflammatory interleukin-6, tumour necrosis factor-α and keratinocyte chemoattractant/growth regulated oncogene were significantly lower compared to the control group demonstrating a systemic anti-inflammatory effect. These changes occurred alongside significant reductions in plasma low density lipoprotein cholesterol and increases in faecal bile acid excretion implying the ability to lower circulating cholesterol via the deconjugation of intestinal bile acids. Correlative analysis identified significant associations between plasma tumour necrosis factor-α and the plasma total cholesterol:high density lipoprotein cholesterol ratio and faecal levels of bifidobacteria in the Lab4 rats. Together, these data highlight Lab4 supplementation as a holistic approach to CVD prevention and encourages further studies in humans.
published_date 2021-11-25T14:06:57Z
_version_ 1822592459185586176
score 11.106734

Similar Items